Citations
1 publicationsPublications from researchers using this productDescription
TEI-9647 is a vitamin D3 lactone analog that specifically inhibits vitamin D receptor activity[1-2]. TEI-9647 has anti-inflammatory effects and has also been used in research exploring the treatment of Paget's disease[3-4].
In vitro, when human promyelocytic leukemia cells (HL-60) were pretreated with TEI-9647 (1nM–1μM) for 24–96 hours, TEI-9647 significantly inhibited HL-60 cell differentiation[5].
In vivo, a single intravenous co-administration of TEI-9647 (2–50μg/kg) with 1α,25(OH)₂D₃ (0.25μg/kg) to vitamin D-deficient rats significantly suppressed the genomic effects of 1α,25(OH)₂D₃ on intestinal calcium transport and bone calcium mobilization 24 hours after treatment[6].
References:
[1] Takenouchi K, Sogawa R, Manabe K, et al. Synthesis and structure-activity relationships of TEI-9647 derivatives as Vitamin D3 antagonists. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):31-4.
[2] Miura D, Manabe K, Ozono K, et al. Antagonistic action of novel 1alpha,25-dihydroxyvitamin D3-26, 23-lactone analogs on differentiation of human leukemia cells (HL-60) induced by 1alpha,25-dihydroxyvitamin D3. J Biol Chem. 1999 Jun 4;274(23):16392-9.
[3] Dixon KM, Deo SS, Wong G, et al. Skin cancer prevention: a possible role of 1,25dihydroxyvitamin D3 and its analogs. J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):137-43.
[4] Díaz L, Noyola-Martínez N, Barrera D, et al. Calcitriol inhibits TNF-alpha-induced inflammatory cytokines in human trophoblasts. J Reprod Immunol. 2009 Jul;81(1):17-24.
[5] Ishizuka S, Kurihara N, Hiruma Y, et al. 1alpha,25-Dihydroxyvitamin D(3)-26,23-lactam analogues function as vitamin D receptor antagonists in human and rodent cells. J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):269-77.
[6] Ishizuka S, Miura D, Ozono K, et al. Antagonistic Actions in Vivo of (23S)-25-Dehydro-1alpha-Hydroxyvitamin D(3-)26,23-Lactone on Calcium Metabolism Induced by 1alpha,25-Dihydroxyvitamin D(3). Endocrinology. 2001 Jan;142(1):59-67.
Protocol
| Cell experiment [1]: | |
Cell lines | HL-60 cells (human promyelocytic leukemia cell line) |
Preparation Method | HL-60 cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were treated with TEI-9647 (1nM-1μM) for 24 hours (gene expression) or 96 hours (differentiation). |
Reaction Conditions | 1nM-1μM for 24 hours (gene expression), 96 hours (HL-60 differentiation). |
Applications | TEI-9647 significantly inhibited differentiation of HL-60 cells. |
| Animal experiment [2]: | |
Animal models | Vitamin D-deficient (-D) rats |
Preparation Method | -D rats were fed a vitamin D-deficient, low calcium diet for 7 weeks. Rats received single intravenous (iv) doses of TEI-9647 (2–50μg/kg) alone or in combination with 1α,25(OH)₂D₃ (0.25–0.5μg/kg). |
Dosage form | 2–50μg/kg; iv; Single injection. |
Applications | TEI-9647 alone weakly stimulated intestinal calcium transport and bone calcium mobilization at 8 hours but not at 24 hours in -D rats. When co-administered with 1α,25(OH)₂D₃, TEI-9647 dose-dependently antagonized 1α,25(OH)₂D₃-induced hypercalcemia, intestinal calcium absorption, and bone calcium mobilization at 24 hours. TEI-9647 also reversed 1α,25(OH)₂D₃-mediated suppression of serum PTH levels. |
References: | |
Product Documents
Chemical Properties
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility
Reviews
Review for TEI-9647
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%
